Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Study Summary

The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.

Conditions

Head and Neck Squamous Cell Carcinoma (HNSCC)Pancreatic Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma Triple Negative Breast Cancer (TNBC)

Interventions / Drugs

GTAEXS617 SoC

View on ClinicalTrials.gov ↗

Sponsor

RXRX

Recursion Pharmaceuticals

AI Drug Discovery

D38/100

Study Details

Enrollment230 participants

Primary Completion—

Lead SponsorExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

Data Retrieved2026-04-11 04:26:31.746357+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.